PL3724191T3 - Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu - Google Patents

Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu

Info

Publication number
PL3724191T3
PL3724191T3 PL18836977T PL18836977T PL3724191T3 PL 3724191 T3 PL3724191 T3 PL 3724191T3 PL 18836977 T PL18836977 T PL 18836977T PL 18836977 T PL18836977 T PL 18836977T PL 3724191 T3 PL3724191 T3 PL 3724191T3
Authority
PL
Poland
Prior art keywords
pyrazolo
difluorophenyl
pyrazol
pyrrolidin
treating cancer
Prior art date
Application number
PL18836977T
Other languages
English (en)
Inventor
Kollol Pal
Stephane Ciblat
Vincent Albert
Nicolas BRUNEAU-LATOUR
Jonathan BOUDREAULT
Original Assignee
Pyramid Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pyramid Biosciences, Inc. filed Critical Pyramid Biosciences, Inc.
Publication of PL3724191T3 publication Critical patent/PL3724191T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL18836977T 2017-12-15 2018-12-12 Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu PL3724191T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599490P 2017-12-15 2017-12-15
EP18836977.1A EP3724191B9 (en) 2017-12-15 2018-12-12 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
PCT/US2018/065187 WO2019118584A1 (en) 2017-12-15 2018-12-12 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
PL3724191T3 true PL3724191T3 (pl) 2022-04-25

Family

ID=65139120

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18836977T PL3724191T3 (pl) 2017-12-15 2018-12-12 Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu
PL22152688.2T PL4053128T3 (pl) 2017-12-15 2018-12-12 Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL22152688.2T PL4053128T3 (pl) 2017-12-15 2018-12-12 Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu

Country Status (26)

Country Link
US (4) US11230546B2 (pl)
EP (2) EP4053128B8 (pl)
JP (1) JP7321183B2 (pl)
KR (1) KR102738182B1 (pl)
CN (1) CN111819179B (pl)
AU (1) AU2018383571B2 (pl)
CA (1) CA3084814A1 (pl)
DK (2) DK4053128T3 (pl)
EA (1) EA202091475A1 (pl)
ES (2) ES2908773T3 (pl)
FI (1) FI4053128T3 (pl)
HR (2) HRP20220464T1 (pl)
HU (2) HUE059313T2 (pl)
IL (1) IL275059B2 (pl)
LT (2) LT4053128T (pl)
MX (1) MX2020006293A (pl)
PL (2) PL3724191T3 (pl)
PT (2) PT4053128T (pl)
RS (1) RS66124B1 (pl)
SA (1) SA520412192B1 (pl)
SG (1) SG11202005237SA (pl)
SI (2) SI3724191T1 (pl)
SM (1) SMT202400435T1 (pl)
TW (1) TWI848925B (pl)
WO (1) WO2019118584A1 (pl)
ZA (2) ZA202003483B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3724191T3 (pl) 2017-12-15 2022-04-25 Pyramid Biosciences, Inc. Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu
GB201813791D0 (en) * 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
WO2020187291A1 (zh) * 2019-03-19 2020-09-24 华中师范大学 吡唑并嘧啶化合物和药物组合物及其应用
CN111718350B (zh) * 2019-03-19 2021-04-13 华中师范大学 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用
CN111848626B (zh) * 2019-04-30 2021-11-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021211882A1 (en) * 2020-04-15 2021-10-21 Pyramid Biosciences, Inc. Methods for preparing tyrosine receptor kinase inhibitors
CN114437077B (zh) * 2020-11-04 2024-01-30 浙江同源康医药股份有限公司 用作激酶抑制剂的化合物及其应用
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
KR102541026B1 (ko) * 2020-11-11 2023-06-12 주식회사 한독 Trk 억제제 화합물의 제조 방법
CN116887834A (zh) * 2020-12-15 2023-10-13 儿童医院医学中心 多环IRAK和flt3抑制化合物以及其用途
US20260028352A1 (en) * 2022-09-07 2026-01-29 Suzhou Langrui Biopharmaceutical Co., Ltd. Macrocyclic imidazo [1,2-b] pyridazine derivative, preparation method therefor, and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EA019507B1 (ru) * 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
PT3106463T (pt) * 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
RU2539568C2 (ru) 2008-10-31 2015-01-20 Дженентек, Инк. Пиразолопиримидиновые соединения-ингибиторы jak и способы
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011029027A1 (en) 2009-09-03 2011-03-10 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012125668A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
US20140288043A1 (en) * 2013-03-19 2014-09-25 Genentech, Inc. Pyrazolopyridine compounds
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
FR3029769A1 (fr) * 2014-12-10 2016-06-17 Tornier Sa Kit pour une prothese d'epaule
CN107207514B (zh) * 2014-12-15 2020-01-24 康联制药有限公司 稠环杂芳基化合物及其作为trk抑制剂的用途
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
JP6475084B2 (ja) 2015-05-21 2019-02-27 臼井国際産業株式会社 トルクセンサ用シャフトの製造設備およびその製造方法
DE102016219374B4 (de) 2016-10-06 2018-06-14 Siemens Aktiengesellschaft Langzeitstabile und stoffschlüssige Strompfadverbindung für Nieder-, Mittelspannungs- und/oder Hochspannungsanlagen bzw. –Schaltgeräte mittels Nanomaterialien
PL3724191T3 (pl) 2017-12-15 2022-04-25 Pyramid Biosciences, Inc. Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu
CN112398593B (zh) 2019-08-13 2024-08-16 上海朗帛通信技术有限公司 一种被用于无线通信的节点中的方法和装置
WO2021211882A1 (en) 2020-04-15 2021-10-21 Pyramid Biosciences, Inc. Methods for preparing tyrosine receptor kinase inhibitors

Also Published As

Publication number Publication date
ZA202003483B (en) 2023-01-25
CN111819179A (zh) 2020-10-23
EP3724191B9 (en) 2022-05-18
IL275059A (en) 2020-07-30
AU2018383571B2 (en) 2023-09-21
KR102738182B1 (ko) 2024-12-03
LT3724191T (lt) 2022-04-25
PT3724191T (pt) 2022-03-07
EP3724191B1 (en) 2022-01-26
DK4053128T3 (da) 2024-10-21
EP3724191A1 (en) 2020-10-21
HRP20220464T1 (hr) 2022-05-27
EA202091475A1 (ru) 2020-09-09
IL275059B1 (en) 2023-07-01
JP7321183B2 (ja) 2023-08-04
TW201936194A (zh) 2019-09-16
AU2018383571A1 (en) 2020-06-18
TWI848925B (zh) 2024-07-21
EP4053128B8 (en) 2024-10-02
US20220235055A1 (en) 2022-07-28
SI3724191T1 (sl) 2022-06-30
ES2992993T3 (en) 2024-12-20
ZA202205900B (en) 2023-11-29
BR112020011775A2 (pt) 2020-11-17
US20210094956A1 (en) 2021-04-01
KR20200099557A (ko) 2020-08-24
CN111819179B (zh) 2023-09-01
PL4053128T3 (pl) 2025-01-27
PT4053128T (pt) 2024-10-15
US11230546B2 (en) 2022-01-25
FI4053128T3 (fi) 2024-10-25
EP4053128B1 (en) 2024-08-21
HRP20241426T1 (hr) 2024-12-20
HUE069285T2 (hu) 2025-02-28
ES2908773T3 (es) 2022-05-03
RS66124B1 (sr) 2024-11-29
SI4053128T1 (sl) 2025-03-31
CA3084814A1 (en) 2019-06-20
US20230124248A1 (en) 2023-04-20
WO2019118584A1 (en) 2019-06-20
US12486276B2 (en) 2025-12-02
JP2021506954A (ja) 2021-02-22
US20240246976A1 (en) 2024-07-25
MX2020006293A (es) 2020-12-03
LT4053128T (lt) 2024-11-25
IL275059B2 (en) 2023-11-01
EP4053128A1 (en) 2022-09-07
SA520412192B1 (ar) 2022-08-11
HUE059313T2 (hu) 2022-11-28
US11739096B2 (en) 2023-08-29
DK3724191T3 (da) 2022-03-14
SMT202400435T1 (it) 2025-01-14
SG11202005237SA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
ZA202003483B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
IL280701A (en) History of 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3,2-dichlorophenyl)-2-methylpyrimidin-4(H3)-one and compounds related as PTPN11 (SHP2) inhibitors for cancer treatment
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
IL265918B (en) Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors
PL3357922T3 (pl) Pochodne 2-((5-(1-(3-(metylosulfonylo)propylo)piperydyn-4-ylo)pirydyn-2-ylo)amino)pirydo[2,3-d]pirymidyn-7(8h)-onu i związki pokrewne jako inhibitory cdk4 do leczenia nowotworów
PT3458456T (pt) Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
NZ598086A (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
IL288529A (en) History of imidazo[2,1-c]pyrimidine as prc2 inhibitors for cancer therapy
HK40029595A (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
PL3621966T3 (pl) Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK